News
See Pharmaceutical Reviews Update – Issue 16 for important news and information related to CADTH’s drug review programs. Highlights from this issue include:
a consultation on CADTH’s drug reimbursement review procedures
a consultation on the Health Canada, CADTH, and INESSS aligned review process
changes to the prov...
Canadian policy-makers face challenges with the number of drugs for rare indications and rapidly rising costs. In facing these challenges, decision-makers see real-world evidence (RWE) as an opportunity.
Health Canada and CADTH recently announced the intent to co-develop an action plan to optimize the process for systematically using and integr...
On March 24, Dr. Maurice McGregor turned 100.
Dr. McGregor is affectionately known as the “grandfather of health technology assessment” in Canada. In 2014 CADTH acknowledged his enduring legacy and his immeasurable contributions to Canadian health care by establishing an award in his name. This award is presented annually to “rising stars” in t...
Media Advisory
Huge response to upcoming CADTH webinar on remdesivir and hydroxychloroquine shows demand among health care decision-makers for evidence on the effectiveness of these therapies.
Ottawa, Ontario — More than 1,500 people have registered for a CADTH webinar that will provide an overview of the available science behind remdesivir an...
CADTH has received the following notice(s) of pending drug submission(s).
Brand name
Zolgensma
Generic name
onasemnogene abeparvovec
Manufacturer
Novartis Pharmaceuticals Canada Inc.
Indication(s)
Spinal muscular atrophy (SMA), pediatrics
Project Number
SG0649-000
Call for pat...
